Using plasma proteomics to understand diseases of the brain: Alzheimer’s & cerebral small vessel disease

Using plasma proteomics to understand diseases of the brain: Alzheimer’s & cerebral small vessel disease

Abstract

Recent advances in high-throughput technology for the characterization of the human proteome have enabled the simultaneous assessment of thousands of circulating proteins at scale. Using this technology to examine plasma proteomic changes that precede the onset of dementia and Alzheimer’s disease may provide a window into the underlying disease biology and nominate new biomarkers and targets for intervention. By applying SomaLogic’s SomaScan® Assay to conduct a large-scale prospective analysis of the plasma proteome in cognitively normal individuals who later progress to dementia, we take a data-driven approach to discovery of early-stage blood-based biomarkers for Alzheimer’s disease, dementia, and cerebral small vessel disease. Through multi-cohort efforts which leverage network-based proteomics, genetics, brain imaging, and cerebral spinal fluid (CSF) biomarkers, we have identified a novel set of proteins, protein networks, and related biological pathways that may play a mechanistic role in age-related neurodegenerative conditions, including Alzheimer’s disease and vascular cognitive impairment.

Learning Objectives

This presentation will demonstrate how proteins measured in blood decades before dementia onset can be combined with genetic data to (1) identify novel early biomarkers for dementia, Alzheimer’s disease, and brain MRI characteristics indicative of cerebral small vessel disease, and (2) better understand the molecular pathways altered in the preclinical and prodromal phase of neurodegenerative disease. This presentation will also illustrate how SomaLogic’s SomaSignal® Tests can be used to enhance our understanding of how health characteristics and subclinical disease states influence brain aging and development of neurodegenerative disease.

  • In middle-aged adults we identified proteins associated with dementia risk over a 25-year of follow-up period
  • Proteins involved in proteostasis, immunity, synaptic function, and extracellular matrix organization were most strongly implicated in dementia risk
  • Proteomics in combination with brain neuroimaging yielded insight about the biological processes underlying cerebral small vessel disease
  • Incorporating genetic methods allowed us to nominate potentially causal proteins and genetically validate biomarkers
  • SomaSignal Tests can be used to understand how health characteristics may influence Alzheimer’s disease and dementia risk

Image of Dr Keenan Walker

Keenan Walker, Ph.D.

Tenure-Track Investigator
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND) Unit
Laboratory of Behavioral Neuroscience
National Institute on Aging, Intramural Research Program

 

Using plasma proteomics to understand diseases of the brain: Alzheimer’s & cerebral small vessel disease

A webinar presented by Keenan Walker, PhD

Request Information


Share with colleagues

More webinars

WebinarUtilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure 

Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.

Learn more

WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases

Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Learn more

WebinarProteomics for precision neuroscience: The power of protein analysis

This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.

Learn more

Explore webinars in our interactive viewer